Ozmosi | Decernotinib Drug Profile

Product Description

Mechanisms of Action: JAK1 Inhibitor, JAK2 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Vertex
Company Location: Eastern America
Company CEO: Reshma Kewalramani
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Arthritis, Rheumatoid

Phase 1: Healthy Volunteers

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Latest Trial Update Date	Data Updated
NCT01886209	VX13-509-010	P1	Completed	Healthy Volunteers	2013-08-01	2019-03-19
NCT00789126	VX08-509-002	P1	Completed	Healthy Volunteers	None	2019-03-18	Treatments
2011-004419-22	2011-004419-22	P2	Completed	Arthritis, Rheumatoid	2014-07-31	2022-03-13	Treatments
NCT01590459	VX11-509-102	P2	Completed	Arthritis, Rheumatoid	2014-07-01	2019-03-19	Treatments
2012-003439-41	2012-003439-41	P2	Completed	Arthritis, Rheumatoid	2014-04-25	2022-03-13	Treatments
NCT01754935	VX12-509-103	P2	Completed	Arthritis, Rheumatoid	2014-01-01	2019-03-19	Treatments
2009-017438-32	2009-017438-32	P2	Completed	Arthritis, Rheumatoid	2011-07-11	2022-03-13	Treatments
NCT01052194	VX09-509-101	P2	Completed	Arthritis, Rheumatoid	2011-07-01	2019-03-19	Treatments
2012-004342-14	2012-004342-14	P3	Terminated	Arthritis, Rheumatoid	2014-07-28	2025-06-28	Treatments
NCT01830985	VX12-509-104	P3	Completed	Arthritis, Rheumatoid	2014-07-01	2019-03-19	Treatments

Recent News Events

Date	Type	Title
02/26/2024	PubMed	VX-509 attenuates the stemness characteristics of colorectal cancer stem-like cells by regulating the epithelial-mesenchymal transition through Nodal/Smad2/3 signaling.
10/05/2023	PubMed	Azaindole derivatives as potential kinase inhibitors and their SARs elucidation.
02/28/2023	PubMed	Okadaic Acid Activates JAK/STAT Signaling to Affect Xenobiotic Metabolism in HepaRG Cells.
04/24/2019	News Article	Aclaris Therapeutics Announces Issuance of a Patent Covering the use of Ruxolitinib and its Deuterated Forms to Treat Alopecia Areata

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Decernotinib

Alternative Names: decernotinib, vx-509 Clinical Status: Inactive Latest Update: 2024-02-26 Latest Update Note: PubMed Publication